223 related articles for article (PubMed ID: 22156929)
41. The molecular basis of adrenocortical cancer.
Lehmann T; Wrzesinski T
Cancer Genet; 2012 Apr; 205(4):131-7. PubMed ID: 22559973
[TBL] [Abstract][Full Text] [Related]
42. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
43. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
44. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
Foote M
Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
[TBL] [Abstract][Full Text] [Related]
45. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
46. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
47. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
48. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
50. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?
Li C; Li Y; Gao Y; Wei N; Zhao X; Wang C; Li Y; Xiu X; Cui J
Int J Pharm; 2014 Jul; 468(1-2):15-25. PubMed ID: 24709221
[TBL] [Abstract][Full Text] [Related]
51. Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy.
Jiang X; Li H; Zhao P; Xie J; Khabele D; Xu J; Gore JC
Neoplasia; 2016 Jun; 18(6):387-97. PubMed ID: 27292027
[TBL] [Abstract][Full Text] [Related]
52. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
[TBL] [Abstract][Full Text] [Related]
53. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
[TBL] [Abstract][Full Text] [Related]
54. Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management.
Schiavon A; Saba L; Catucci G; Petiti J; Puglisi S; Borin C; Reimondo G; Gilardi G; Giachino C; Terzolo M; Lo Iacono M
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069023
[TBL] [Abstract][Full Text] [Related]
55. Gene expression profiling of childhood adrenocortical tumors.
West AN; Neale GA; Pounds S; Figueredo BC; Rodriguez Galindo C; Pianovski MA; Oliveira Filho AG; Malkin D; Lalli E; Ribeiro R; Zambetti GP
Cancer Res; 2007 Jan; 67(2):600-8. PubMed ID: 17234769
[TBL] [Abstract][Full Text] [Related]
56. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
57. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells.
Wang C; Ho PC; Lim LY
Int J Pharm; 2010 Nov; 400(1-2):201-10. PubMed ID: 20804835
[TBL] [Abstract][Full Text] [Related]
58. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
59. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.
Bressand D; Novell A; Girault A; Raoul W; Fromont-Hankard G; Escoffre JM; Lecomte T; Bouakaz A
Mol Pharm; 2019 Sep; 16(9):3814-3822. PubMed ID: 31356090
[TBL] [Abstract][Full Text] [Related]
60. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]